Sugi Predict

Sugi Predict / Compounds / Naphthyridinone

Naphthyridinone

Naphthyridinone

SCHEMBL762298

CC(=O)Nc1c(C(C)=O)c(=O)n(C)c2nc(-c3ccc(Cl)cc3Cl)c(-c3ccc(Cl)cc3)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CNR1 P21554 20/20 1.00
▸ CNR2 P34972 19/20 1.00
▸ GABRA1 P14867 2/20 1.00
▸ ADRA2C P18825 2/20 1.00
▸ SLC6A3 Q01959 2/20 1.00
▸ EGFR P00533 1/20 1.00
▸ ALOX5 P09917 1/20 1.00
▸ ADORA3 P0DMS8 1/20 1.00
▸ MAPK3 P27361 1/20 1.00
▸ OPRL1 P41146 1/20 1.00
▸ SLC18A2 Q05940 1/20 1.00
▸ MAPK14 Q16539 1/20 1.00
▸ TMEM97 Q5BJF2 1/20 1.00
▸ SIGMAR1 Q99720 1/20 1.00
▸ ADRB3 P13945 1/20 0.78
▸ ADRA2B P18089 1/20 0.78
▸ HTR2A P28223 1/20 0.78
▸ HTR2C P28335 1/20 0.78
▸ OPRD1 P41143 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3616208 0.95 CNR1 (0.91) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3619840 0.92 CNR1 (0.86) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3619245 0.92 CNR1 (1.00) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3620523 0.92 CNR1 (0.84) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3622930 0.91 CNR1 (0.84) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3621932 0.91 CNR1 (0.83) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3624184 0.91 CNR1 (0.83) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3627613 0.90 CNR1 (0.84) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3623463 0.90 CNR1 (0.82) CNR1CNR2GABRA1ADRA2CSLC6A3
SCHEMBL3624716 0.90 CNR1 (1.00) CNR1CNR2GABRA1ADRA2CSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728141-B2 Substituted naphthyridinone derivatives MERCK SHARP & DOHME CORP. (US) 2010-06-01 — — US claimed
EP-1682550-B1 SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES MERCK & CO INC (US) 2009-12-23 — — EP claimed
JP-2007510649-A — — 2007-04-26 — — JP claimed
US-20070032517-A1 Substituted naphthyridinone derivatives MERCK SHARP & DOHME CORP. 2007-02-08 — — US claimed
EP-1682550-A4 SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES MERCK & CO INC (US) 2007-01-03 — — EP claimed
EP-1682550-A1 SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES Merck & Co., Inc. (US) 2006-07-26 — — EP claimed
WO-2005047285-A1 SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES MERCK & CO., INC. (US) 2005-05-26 — — WO claimed
EP-4720063-A1 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER Novartis AG (CH) 2026-04-08 — — EP disclosed
EP-4720063-A1 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER Novartis AG (CH) 2026-04-08 — — EP disclosed
EP-4678641-A1 QUINOLINONE COMPOUND AND NAPHTHYRIDINONE COMPOUND AND USE THEREOF Shanghai Helioson Pharmaceutical Co., Ltd. (CN) 2026-01-14 — — EP disclosed
EP-4656240-A1 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER Novartis AG (CH) 2025-12-03 — — EP disclosed
EP-4436662-B1 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2025-09-17 — — EP disclosed
US-20250214989-A1 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER NOVARTIS AG (CH) 2025-07-03 — — US disclosed
US-20080214559-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARMACEUTICALS B.V. 2008-09-04 — — US disclosed
WO-2008084057-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION SOLVAY PHARMACEUTICALS B.V. (NL) 2008-07-17 — — WO disclosed
US-20080153867-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION SOLVAY PHARMACEUTICALS B.V. 2008-06-26 — — US disclosed
WO-2008074816-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION SOLVAY PHARMACEUTICALS B.V. (NL) 2008-06-26 — — WO disclosed
US-20070032517-A1 Substituted naphthyridinone derivatives MERCK SHARP & DOHME CORP. 2007-02-08 — — US disclosed
US-20070032517-A1 Substituted naphthyridinone derivatives MERCK SHARP & DOHME CORP. 2007-02-08 — — US disclosed
US-20070032517-A1 Substituted naphthyridinone derivatives MERCK SHARP & DOHME CORP. 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214989-A1 NAPHTHYRIDINONE DERIVATIVES FOR THE TREATMENT OF A DISEASE OR DISORDER PKD1, PKD2, ASAH2 CNR1 1267/4885CNR2 1960/4885GABRA1 2921/4885
US-20080153867-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID-CB1 ANTAGONISM AND ACETYLCHOLINESTERASE INHIBITION ACHE, BACE1, BCHE CNR1 4/4885CNR2 5/4885GABRA1 1085/4885
US-20070032517-A1 Substituted naphthyridinone derivatives CNR1, CNR2, MAG CNR1 1/4885CNR2 2/4885GABRA1 56/4885
US-20080214559-A1 COMPOUNDS WITH A COMBINATION OF CANNABINOID CB1 ANTAGONISM AND SEROTONIN REUPTAKE INHIBITION CNR1, OPRL1, CNR2 CNR1 1/4885CNR2 3/4885GABRA1 301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.